V. Karkischenko, A. G. Berzina, N. V. Petrova, I. A. Pomytkin, E. S. Glotova, D. V. Petrov, L. A. Taboyakova, L. A. Bolotskih, N. А. Laryushina
{"title":"Evidence for the Presence of β2m hom Target Proteins and HLA in Humanized Transgenic Mice of HLA-A*02:01, HLA-B*07:02, and HLA-C*07:02 Lines","authors":"V. Karkischenko, A. G. Berzina, N. V. Petrova, I. A. Pomytkin, E. S. Glotova, D. V. Petrov, L. A. Taboyakova, L. A. Bolotskih, N. А. Laryushina","doi":"10.33647/2074-5982-20-2-32-44","DOIUrl":null,"url":null,"abstract":"Human leukocyte antigen plays a primary role in the formation of immune response and pathogenesis of diseases of various etiologies, including the development of negative side effects induced by pharmacological agents. Modern pharmacosafety standards require improvement of existing test systems to conduct high-quality preclinical studies. A number of humanized transgenic mouse lines with hybrid HLA I class molecules on the cell surface, which correspond to the human allelic variants HLA-A*02:01, HLA-B*07:02, and HLA-C*07:02, were developed at the Scientific Center of Biomedical Technologies of the Federal Medical and Biological Agency of Russia. In this article, we present experimental data on quantitative determination of β2-microglobulin protein and HLA by the “sandwich” ELISA method in mice with different alleles of HLA I class genes. The results obtained confirm the presence of target functional proteins (transgenicity) in humanized transgenic mice, which is consistent with our previous data obtained when determining the primary sequence of the transgene using Sanger sequencing. We also discuss the scientific and practical significance of such biomodels, as well as the scope of their application.","PeriodicalId":14837,"journal":{"name":"Journal Biomed","volume":"16 12","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal Biomed","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33647/2074-5982-20-2-32-44","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Human leukocyte antigen plays a primary role in the formation of immune response and pathogenesis of diseases of various etiologies, including the development of negative side effects induced by pharmacological agents. Modern pharmacosafety standards require improvement of existing test systems to conduct high-quality preclinical studies. A number of humanized transgenic mouse lines with hybrid HLA I class molecules on the cell surface, which correspond to the human allelic variants HLA-A*02:01, HLA-B*07:02, and HLA-C*07:02, were developed at the Scientific Center of Biomedical Technologies of the Federal Medical and Biological Agency of Russia. In this article, we present experimental data on quantitative determination of β2-microglobulin protein and HLA by the “sandwich” ELISA method in mice with different alleles of HLA I class genes. The results obtained confirm the presence of target functional proteins (transgenicity) in humanized transgenic mice, which is consistent with our previous data obtained when determining the primary sequence of the transgene using Sanger sequencing. We also discuss the scientific and practical significance of such biomodels, as well as the scope of their application.